Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Guided Therapeutics (GTHP) over the last 15 years, with Q3 2025 value amounting to $181000.0.

  • Guided Therapeutics' Cash from Financing Activities fell 5382.65% to $181000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 7133.11%. This contributed to the annual value of $916000.0 for FY2024, which is 371666.67% up from last year.
  • Guided Therapeutics' Cash from Financing Activities amounted to $181000.0 in Q3 2025, which was down 5382.65% from $239000.0 recorded in Q2 2025.
  • Guided Therapeutics' 5-year Cash from Financing Activities high stood at $2.9 million for Q3 2022, and its period low was -$154000.0 during Q3 2023.
  • Its 5-year average for Cash from Financing Activities is $350789.5, with a median of $181000.0 in 2025.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 68787.88% in 2022, then plummeted by 30000.0% in 2024.
  • Quarter analysis of 5 years shows Guided Therapeutics' Cash from Financing Activities stood at -$53000.0 in 2021, then grew by 20.75% to -$42000.0 in 2022, then surged by 566.67% to $196000.0 in 2023, then surged by 168.37% to $526000.0 in 2024, then tumbled by 65.59% to $181000.0 in 2025.
  • Its Cash from Financing Activities was $181000.0 in Q3 2025, compared to $239000.0 in Q2 2025 and $58000.0 in Q1 2025.